Pertuzumab Market - Size, Share, Outlook, and
Opportunity Analysis 2018 – 2026
Pertuzumab is a recombinant monoclonal antibody that acts as an antineoplastic agent, which
targets the human epidermal growth factor receptor 2 protein known as HER2. The drug blocks
signaling pathways that leads to cell growth arrest and apoptosis (cell destruction), thereby
inhibiting the proliferation of human tumor cells. Pertuzumab was found to aid in the treatment
of HER2 associated breast cancer and was developed by Genentech, Inc., a subsidiary of F.
Hoffmann-La Roche AG. It was first approved by U.S. Food and Drug Administration in 2012.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2256
Pertuzumab Market– Drivers
There are increasing number of clinical trials for use of pertuzumab in combination with other
drugs for the treatment of breast cancer . For instance, Helsinki University Central Hospital is
undergoing phase III clinical study for adjuvant trastuzumab, pertuzumab, and docetaxel in the
treatment of early HER2 positive breast cancer. The study was started in December 2015 and is
estimated to complete by June 2023.
Furthermore, increasing number of drug approvals are expected to propel growth of the global
pertuzumab market. For instance, in December 2017, the U.S. Food and Drug Administration
(U.S FDA) granted approval to PERJETA, a pertuzumab produced by Genentech, Inc. for its use
in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with
HER2-positive early breast cancer at high risk of recurrence.
Moreover, development of novel anticancer drug delivery technologies is expected to boost
growth of the market. For instance, in July 2018, Gentech, Inc., in partnership with Halozyme
Therapeutics, Inc., used proprietary ENHANZE drug-delivery technology of Halozyme
Therapeutics, Inc., for subcutaneous administration of fixed-dose combination of pertuzumab
(PERJETA) and trastuzumab (Herceptin). This study is under clinical phase III trial. ENHANZE
technology aids in reducing the need for multiple injections and reduces time required for drug
administration.